Company
Nurix Therapeutics
Nurix is writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease.
Also known as Nurix, Nurix Therapeutics, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Nurix Therapeutics, Inc.
- nurixtx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases.
Funding snapshot
- Total raised
- $145MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $120M2020-03-09
Funding rounds
- Round, 2020
- $120M2020-03-09, SEC form D sold, 23 investors
- Round, 2015
- $17M2015-09-03, SEC form D sold, 1 investor
- Round, 2013
- $2.1M2013-12-18, SEC form D sold, 2 investors
- Round, 2012
- $5.3M2012-04-30, SEC form D sold, 4 investors
- Round, 2012
- $1.8K2012-04-07, SEC form D sold, 1 investor
Products
- Web
- Degrader-Antibody Conjugates (DACs)
- Web
- Degraders
Loading relationship preview